BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Sold by US Bancorp DE

US Bancorp DE cut its stake in BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) by 40.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,819 shares of the medical equipment provider’s stock after selling 16,842 shares during the quarter. US Bancorp DE’s holdings in BioLife Solutions were worth $564,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. increased its position in shares of BioLife Solutions by 1.6% during the 1st quarter. BlackRock Inc. now owns 3,712,680 shares of the medical equipment provider’s stock worth $84,390,000 after purchasing an additional 57,623 shares during the last quarter. Vanguard Group Inc. increased its position in shares of BioLife Solutions by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 2,201,602 shares of the medical equipment provider’s stock worth $50,043,000 after purchasing an additional 54,344 shares during the last quarter. Millennium Management LLC increased its position in shares of BioLife Solutions by 45.3% during the 2nd quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider’s stock worth $21,545,000 after purchasing an additional 486,631 shares during the last quarter. State Street Corp increased its position in shares of BioLife Solutions by 26.1% during the 2nd quarter. State Street Corp now owns 1,270,364 shares of the medical equipment provider’s stock worth $17,544,000 after purchasing an additional 263,021 shares during the last quarter. Finally, Gagnon Securities LLC increased its position in shares of BioLife Solutions by 50.6% during the 2nd quarter. Gagnon Securities LLC now owns 571,679 shares of the medical equipment provider’s stock worth $7,895,000 after purchasing an additional 192,173 shares during the last quarter. 89.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. StockNews.com upgraded BioLife Solutions to a “sell” rating in a report on Monday, November 21st. Stephens lowered their target price on BioLife Solutions to $31.00 in a report on Wednesday, November 16th.

Insider Activity

In other news, CMO Todd Berard sold 6,500 shares of BioLife Solutions stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total value of $162,760.00. Following the completion of the transaction, the chief marketing officer now owns 119,265 shares in the company, valued at approximately $2,986,395.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other BioLife Solutions news, CMO Todd Berard sold 6,500 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total transaction of $162,760.00. Following the transaction, the chief marketing officer now owns 119,265 shares of the company’s stock, valued at $2,986,395.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $17.77, for a total value of $177,700.00. Following the transaction, the executive vice president now directly owns 252,826 shares in the company, valued at approximately $4,492,718.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,890 shares of company stock worth $2,368,802. 3.30% of the stock is currently owned by company insiders.

BioLife Solutions Stock Performance

Shares of BLFS opened at $24.45 on Friday. The stock has a 50-day simple moving average of $20.35 and a 200-day simple moving average of $21.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.76 and a current ratio of 3.68. The stock has a market capitalization of $1.05 billion, a PE ratio of -9.86 and a beta of 1.75. BioLife Solutions, Inc. has a 1 year low of $10.40 and a 1 year high of $31.11.

BioLife Solutions (NASDAQ:BLFSGet Rating) last announced its quarterly earnings data on Wednesday, November 9th. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $40.75 million during the quarter, compared to analysts’ expectations of $41.63 million. BioLife Solutions had a negative net margin of 67.70% and a negative return on equity of 7.50%. On average, analysts predict that BioLife Solutions, Inc. will post -0.63 earnings per share for the current fiscal year.

About BioLife Solutions

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Recommended Stories

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating).

Institutional Ownership by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.